NovaBay Pharmaceuticals to Hold Third Quarter 2019 Conference Call on November 7, 2019

NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it will report third quarter 2019 financial results after market close on Thursday, November 7, 2019 and will hold an investment community conference call that day.

DATE:

 

Thursday, November 7

TIME:

 

4:30 p.m. ET / 1:30 p.m. PT

DIAL IN:

 

800-608-8202 from within the U.S.

 

 

702-495-1913 from outside the U.S.

 

 

Enter conference identification number 5868436

The live call also will be available at http://novabay.com/investors/events. A replay of the call will be available beginning two hours after its completion through 11:59 p.m. Eastern time November 25, 2019, by dialing 855-859-2056 from within the U.S. or 404-537-3406 from outside the U.S. and entering the conference identification number 5868436. The call will also be archived at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Socialize and Stay informed on NovaBay’s progress: Like us on Facebook Follow us on Twitter Connect with NovaBay on LinkedIn Join us on Google+ Visit NovaBay’s Website

Avenova Purchasing Information For NovaBay Avenova purchasing information: Please call 800-890-0329 or email [e-mail]. www.Avenova.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20191031005135/en/

NovaBay Contact Justin Hall, President and Chief Executive Officer 510-899-8800 [e-mail]

Investor Contact LHA Investor Relations Jody Cain 310-691-7100 [e-mail]